Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2017, Article ID 7058424, 19 pages
https://doi.org/10.1155/2017/7058424
Review Article

MicroRNAs-Dependent Regulation of PPARs in Metabolic Diseases and Cancers

Department of Cell Physiology and Metabolism and Diabetes Center, Faculty of Medicine, University of Geneva, Geneva, Switzerland

Correspondence should be addressed to Michelangelo Foti; hc.eginu@itof.olegnalehcim

Received 24 August 2016; Accepted 5 December 2016; Published 12 January 2017

Academic Editor: Valeria Amodeo

Copyright © 2017 Dorothea Portius et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. Issemann and S. Green, “Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators,” Nature, vol. 347, no. 6294, pp. 645–650, 1990. View at Publisher · View at Google Scholar · View at Scopus
  2. R. M. Evans, G. D. Barish, and Y.-X. Wang, “PPARs and the complex journey to obesity,” Nature Medicine, vol. 10, no. 4, pp. 355–361, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. S. Polvani, “Peroxisome proliferator activated receptors at the crossroad of obesity, diabetes, and pancreatic cancer,” World Journal of Gastroenterology, vol. 22, no. 8, pp. 2441–2459, 2016. View at Publisher · View at Google Scholar
  4. G. M. G. Attianese and B. Desvergne, “Integrative and systemic approaches for evaluating PPARβ/δ (PPARD) function,” Nuclear Receptor Signaling, 2015. View at Publisher · View at Google Scholar
  5. M. Ahmadian, J. M. Suh, N. Hah et al., “PPARγ signaling and metabolism: the good, the bad and the future,” Nature Medicine, vol. 19, no. 5, pp. 557–566, 2013. View at Publisher · View at Google Scholar
  6. B. Grygiel-Górniak, “Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications—a review,” Nutrition Journal, vol. 13, no. 1, article no. 17, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. J. M. Peters, Y. M. Shah, and F. J. Gonzalez, “The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention,” Nature Reviews Cancer, vol. 12, no. 3, pp. 181–195, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. A. S. Laganà, S. G. Vitale, A. Nigro et al., “Pleiotropic actions of Peroxisome Proliferator-Activated Receptors (PPARs) in dysregulated metabolic homeostasis, inflammation and cancer: current evidence and future perspectives,” International Journal of Molecular Sciences, vol. 17, no. 7, article 999, 2016. View at Publisher · View at Google Scholar
  9. E. Fuentes, L. Guzmán-Jofre, R. Moore-Carrasco, and I. Palomo, “Role of PPARs in inflammatory processes associated with metabolic syndrome (Review),” Molecular Medicine Reports, vol. 8, no. 6, pp. 1611–1616, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. C. J. Bailey, A. A. Tahrani, and A. H. Barnett, “Future glucose-lowering drugs for type 2 diabetes,” The Lancet Diabetes and Endocrinology, vol. 4, no. 4, pp. 350–359, 2016. View at Publisher · View at Google Scholar · View at Scopus
  11. B. Gross and B. Staels, “PPAR agonists: multimodal drugs for the treatment of type-2 diabetes,” Best Practice and Research in Clinical Endocrinology and Metabolism, vol. 21, no. 4, pp. 687–710, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. S. Sugii and R. M. Evans, “Epigenetic codes of PPARγ in metabolic disease,” FEBS Letters, vol. 585, no. 13, pp. 2121–2128, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. C. V. Rizos, A. Kei, and M. S. Elisaf, “The current role of thiazolidinediones in diabetes management,” Archives of Toxicology, vol. 90, no. 8, pp. 1861–1881, 2016. View at Publisher · View at Google Scholar
  14. R. Barres and J. R. Zierath, “DNA methylation in metabolic disorders,” American Journal of Clinical Nutrition, vol. 93, no. 4, pp. 897S–900S, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Fujiki, F. Kano, K. Shiota, and M. Murata, “Expression of the peroxisome proliferator activated receptor γ gene is repressed by DNA methylation in visceral adipose tissue of mouse models of diabetes,” BMC Biology, vol. 7, article no. 38, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. M. K. Ramlee, Q. Zhang, M. Idris et al., “Histone H3 K27 acetylation marks a potent enhancer element on the adipogenic master regulator gene Pparg2,” Cell Cycle, vol. 13, no. 21, pp. 3414–3422, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Dharap, C. Pokrzywa, S. Murali, B. Kaimal, and R. Vemuganti, “Mutual induction of transcription factor PPARγ and microRNAs miR-145 and miR-329,” Journal of Neurochemistry, vol. 135, no. 1, pp. 139–146, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. W. Liu, P. Bi, T. Shan et al., “miR-133a regulates adipocyte browning in vivo,” PLOS Genetics, vol. 9, no. 7, Article ID e1003626, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. V. Rottiers and A. M. Näär, “MicroRNAs in metabolism and metabolic disorders,” Nature Reviews Molecular Cell Biology, vol. 13, no. 4, pp. 239–251, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. Z. Yang, T. Cappello, and L. Wang, “Emerging role of microRNAs in lipid metabolism,” Acta Pharmaceutica Sinica B, vol. 5, no. 2, pp. 145–150, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. J. A. Deiuliis, “MicroRNAs as regulators of metabolic disease: pathophysiologic significance and emerging role as biomarkers and therapeutics,” International Journal of Obesity, vol. 40, no. 1, pp. 88–101, 2016. View at Publisher · View at Google Scholar · View at Scopus
  22. C. L. Holley and V. K. Topkara, “An introduction to small non-coding RNAs: miRNA and snoRNA,” Cardiovascular Drugs and Therapy, vol. 25, no. 2, pp. 151–159, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. S. L. Ameres and P. D. Zamore, “Diversifying microRNA sequence and function,” Nature Reviews Molecular Cell Biology, vol. 14, no. 8, pp. 475–488, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. M. A. Goldgraben, R. Russell, O. M. Rueda, C. Caldas, and A. Git, “Double-stranded microRNA mimics can induce length-and passenger strand-dependent effects in a cell type-specific manner,” RNA, vol. 22, no. 2, pp. 193–203, 2016. View at Publisher · View at Google Scholar · View at Scopus
  25. C. Fernandez-Hernando, C. M. Ramírez, L. Goedeke, and Y. Suárez, “MicroRNAs in metabolic disease,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 33, no. 2, pp. 178–185, 2013. View at Publisher · View at Google Scholar
  26. E. van Rooij and S. Kauppinen, “Development of microRNA therapeutics is coming of age,” EMBO Molecular Medicine, vol. 6, no. 7, pp. 851–864, 2014. View at Publisher · View at Google Scholar · View at Scopus
  27. A. Lujambio and S. W. Lowe, “The microcosmos of cancer,” Nature, vol. 482, no. 7385, pp. 347–355, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. G. A. Calin and C. M. Croce, “MicroRNA signatures in human cancers,” Nature Reviews Cancer, vol. 6, no. 11, pp. 857–866, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. C. Sobolewski, N. Calo, D. Portius, and M. Foti, “MicroRNAs in fatty liver disease,” Seminars in Liver Disease, vol. 35, no. 1, pp. 12–25, 2015. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Drakaki, M. Hatziapostolou, C. Polytarchou et al., “Functional microRNA high throughput screening reveals miR-9 as a central regulator of liver oncogenesis by affecting the PPARA-CDH1 pathway,” BMC Cancer, vol. 15, no. 1, article no. 542, 2015. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Cui, Z. Xiao, Y. Wang et al., “Long noncoding RNA HULC modulates abnormal lipid metabolism in hepatoma cells through an mir-9-mediated RXRA signaling pathway,” Cancer Research, vol. 75, no. 5, pp. 846–857, 2015. View at Publisher · View at Google Scholar · View at Scopus
  32. L. Zheng, G.-C. Lv, J. Sheng, and Y.-D. Yang, “Effect of miRNA-10b in regulating cellular steatosis level by targeting PPAR-α expression, a novel mechanism for the pathogenesis of NAFLD,” Journal of Gastroenterology and Hepatology, vol. 25, no. 1, pp. 156–163, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Zhou, K.-C. Wang, W. Wu et al., “MicroRNA-21 targets peroxisome proliferators-activated receptor-α in an autoregulatory loop to modulate flow-induced endothelial inflammation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 25, pp. 10355–10360, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. X. Loyer, V. Paradis, C. Hénique et al., “Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPARa expression,” Gut, vol. 65, no. 11, pp. 1882–1894, 2015. View at Publisher · View at Google Scholar · View at Scopus
  35. Z.-J. Li, P.-H. Ou-Yang, and X.-P. Han, “Profibrotic effect of miR-33a with Akt activation in hepatic stellate cells,” Cellular Signalling, vol. 26, no. 1, pp. 141–148, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. W. Hu, X. Wang, X. Ding et al., “MicroRNA-141 represses HBV replication by targeting PPARA,” PLoS ONE, vol. 7, no. 3, Article ID e34165, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. B. Li, Z. Zhang, H. Zhang et al., “Aberrant miR199a-5p/caveolin1/PPARα axis in hepatic steatosis,” Journal of Molecular Endocrinology, vol. 53, no. 3, pp. 393–403, 2014. View at Publisher · View at Google Scholar
  38. J. L. Tong, C. P. Zhang, F. Nie et al., “MicroRNA 506 regulates expression of PPAR alpha in hydroxycamptothecin- resistant human colon cancer cells,” FEBS Letters, vol. 585, no. 22, pp. 3560–3568, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. R. Martinelli, C. Nardelli, V. Pilone et al., “MiR-519d overexpression is associated with human obesity,” Obesity, vol. 18, no. 11, pp. 2170–2176, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. P. Gurha, T. Wang, A. H. Larimore et al., “microRNA-22 promotes heart failure through coordinate suppression of PPAR/ERR-nuclear hormone receptor transcription,” PLoS ONE, vol. 8, no. 9, Article ID e75882, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. L. Sun and M. Trajkovski, “MiR-27 orchestrates the transcriptional regulation of brown adipogenesis,” Metabolism: Clinical and Experimental, vol. 63, no. 2, pp. 272–282, 2014. View at Publisher · View at Google Scholar · View at Scopus
  42. D. Baek, J. Villén, C. Shin, F. D. Camargo, S. P. Gygi, and D. P. Bartel, “The impact of microRNAs on protein output,” Nature, vol. 455, no. 7209, pp. 64–71, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. H. El Azzouzi, S. Leptidis, E. Dirkx et al., “The Hypoxia-Inducible MicroRNA Cluster miR-199a~214 targets myocardial PPARδ and impairs mitochondrial fatty acid oxidation,” Cell Metabolism, vol. 18, no. 3, pp. 341–354, 2013. View at Publisher · View at Google Scholar · View at Scopus
  44. P. Thulin, T. Wei, O. Werngren et al., “MicroRNA-9 regulates the expression of peroxisome proliferator-activated receptor δ in human monocytes during the inflammatory response,” International Journal of Molecular Medicine, vol. 31, no. 5, pp. 1003–1010, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. Y.-Y. Xiao, P.-J. Fan, S.-R. Lei, M. Qi, and X.-H. Yang, “MiR-138/peroxisome proliferator-activated receptor β signaling regulates human hypertrophic scar fibroblast proliferation and movement in vitro,” Journal of Dermatology, vol. 42, no. 5, pp. 485–495, 2015. View at Publisher · View at Google Scholar · View at Scopus
  46. J.-F. Zhang, W.-M. Fu, M.-L. He et al., “MiRNA-20a promotes osteogenic differentiation of human mesenchymal stem cells by co-regulating BMP signaling,” RNA Biology, vol. 8, no. 5, pp. 829–838, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. S. Li, J. Li, B.-Y. Fei et al., “MiR-27a promotes hepatocellular carcinoma cell proliferation through suppression of its target gene peroxisome proliferator-activated receptor γ,” Chinese Medical Journal, vol. 128, no. 7, pp. 941–947, 2015. View at Publisher · View at Google Scholar · View at Scopus
  48. B.-Y. Kang, K. K. Park, D. E. Green et al., “Hypoxia mediates mutual repression between microRNA-27a and PPARγ in the pulmonary vasculature,” PLoS ONE, vol. 8, no. 11, Article ID e79503, 2013. View at Publisher · View at Google Scholar · View at Scopus
  49. C. Jennewein, A. Von Knethen, T. Schmid, and B. Brüne, “MicroRNA-27b contributes to lipopolysaccharide-mediated peroxisome proliferator-activated receptor γ (PPARγ) mRNA destabilization,” Journal of Biological Chemistry, vol. 285, no. 16, pp. 11846–11853, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Karbiener, C. Fischer, S. Nowitsch et al., “microRNA miR-27b impairs human adipocyte differentiation and targets PPARgamma,” Biochemical and Biophysical Research Communications, vol. 390, no. 2, pp. 247–251, 2009. View at Google Scholar
  51. J.-J. Lee, A. Drakaki, D. Iliopoulos, and K. Struhl, “MiR-27b targets PPARγ to inhibit growth, tumor progression and the inflammatory response in neuroblastoma cells,” Oncogene, vol. 31, no. 33, pp. 3818–3825, 2012. View at Publisher · View at Google Scholar · View at Scopus
  52. X. Li, Y. Chen, S. Wu et al., “MicroRNA-34a and microRNA-34c promote the activation of human hepatic stellate cells by targeting peroxisome proliferator-activated receptor γ,” Molecular Medicine Reports, vol. 11, no. 2, pp. 1017–1024, 2015. View at Publisher · View at Google Scholar · View at Scopus
  53. D. Povero, N. Panera, A. Eguchi et al., “Lipid-induced hepatocyte-derived extracellular vesicles regulate hepatic stellate cells via microRNA targeting Peroxisome Proliferator-Activated Receptor-γ,” CMGH Cellular and Molecular Gastroenterology and Hepatology, vol. 1, no. 6, pp. 646.e4–663.e4, 2015. View at Publisher · View at Google Scholar · View at Scopus
  54. E. K. Lee, M. J. Lee, K. Abdelmohsen et al., “miR-130 suppresses adipogenesis by inhibiting peroxisome proliferator-activated receptor γ expression,” Molecular and Cellular Biology, vol. 31, no. 4, pp. 626–638, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. K. Tu, X. Zheng, C. Dou et al., “MicroRNA-130b promotes cell aggressiveness by inhibiting peroxisome proliferator-activated receptor gamma in human hepatocellular carcinoma,” International Journal of Molecular Sciences, vol. 15, no. 11, pp. 20486–20499, 2014. View at Publisher · View at Google Scholar · View at Scopus
  56. Y. Jiao, M. Zhu, X. Mao et al., “MicroRNA-130a expression is decreased in Xinjiang Uygur patients with type 2 diabetes mellitus,” American Journal of Translational Research, vol. 7, no. 10, pp. 1984–1991, 2015. View at Google Scholar · View at Scopus
  57. Z. Yang, C. Bian, H. Zhou et al., “MicroRNA hsa-miR-138 inhibits adipogenic differentiation of human adipose tissue-derived mesenchymal stem cells through adenovirus EID-1,” Stem Cells and Development, vol. 20, no. 2, pp. 259–267, 2011. View at Publisher · View at Google Scholar · View at Scopus
  58. J. Sun, Y. Wang, Y. Li, and G. Zhao, “Downregulation of PPARγ by miR-548d-5p suppresses the adipogenic differentiation of human bone marrow mesenchymal stem cells and enhances their osteogenic potential,” Journal of Translational Medicine, vol. 12, no. 1, article no. 168, 2014. View at Publisher · View at Google Scholar · View at Scopus
  59. S. Y. Kim, A. Y. Kim, H. W. Lee et al., “miR-27a is a negative regulator of adipocyte differentiation via suppressing PPARγ expression,” Biochemical and Biophysical Research Communications, vol. 392, no. 3, pp. 323–328, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. X. Hou, J. Tian, J. Geng et al., “MicroRNA-27a promotes renal tubulointerstitial fibrosis via suppressing PPARγ pathway in diabetic nephropathy,” Oncotarget, vol. 7, no. 30, pp. 47760–47776, 2016. View at Publisher · View at Google Scholar
  61. J. Wang, Y. Song, Y. Zhang et al., “Cardiomyocyte overexpression of miR-27b induces cardiac hypertrophy and dysfunction in mice,” Cell Research, vol. 22, no. 3, pp. 516–527, 2012. View at Publisher · View at Google Scholar · View at Scopus
  62. C. Kim, H. Lee, Y. M. Cho, O.-J. Kwon, W. Kim, and E. K. Lee, “TNFα-induced miR-130 resulted in adipocyte dysfunction during obesity-related inflammation,” FEBS Letters, vol. 587, no. 23, pp. 3853–3858, 2013. View at Publisher · View at Google Scholar · View at Scopus
  63. L. Lu, J. Wang, H. Lu et al., “MicroRNA-130a and -130b enhance activation of hepatic stellate cells by suppressing PPARγ expression: a rat fibrosis model study,” Biochemical and Biophysical Research Communications, vol. 465, no. 3, pp. 387–393, 2015. View at Publisher · View at Google Scholar · View at Scopus
  64. X.-D. Liu, F. Cai, L. Liu, Y. Zhang, and A.-L. Yang, “MicroRNA-210 is involved in the regulation of postmenopausal osteoporosis through promotion of VEGF expression and osteoblast differentiation,” Biological Chemistry, vol. 396, no. 4, pp. 339–347, 2015. View at Publisher · View at Google Scholar · View at Scopus
  65. H. Li, M. Xue, J. Xu, and X. Qin, “MiR-301a is involved in adipocyte dysfunction during obesity-related inflammation via suppression of PPARγ,” Pharmazie, vol. 71, no. 2, pp. 84–88, 2016. View at Google Scholar
  66. B.-C. Jeong, I.-H. Kang, and J.-T. Koh, “MicroRNA-302a inhibits adipogenesis by suppressing peroxisome proliferator-activated receptor γ expression,” FEBS Letters, vol. 588, no. 18, pp. 3427–3434, 2014. View at Publisher · View at Google Scholar · View at Scopus
  67. L. Chen, Y. Chen, S. Zhang et al., “MiR-540 as a novel adipogenic inhibitor impairs adipogenesis via suppression of PPARγ,” Journal of Cellular Biochemistry, vol. 116, no. 6, pp. 969–976, 2015. View at Publisher · View at Google Scholar · View at Scopus
  68. M. Pawlak, P. Lefebvre, and B. Staels, “Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease,” Journal of Hepatology, vol. 62, no. 3, pp. 720–733, 2015. View at Publisher · View at Google Scholar · View at Scopus
  69. P. Misra and J. K. Reddy, “Peroxisome proliferator-activated receptor-α activation and excess energy burning in hepatocarcinogenesis,” Biochimie, vol. 98, no. 1, pp. 63–74, 2014. View at Publisher · View at Google Scholar · View at Scopus
  70. R. K. Lyn, R. Singaravelu, S. Kargman et al., “Stearoyl-CoA desaturase inhibition blocks formation of hepatitis C virus-induced specialized membranes,” Scientific Reports, vol. 4, article 4549, 2014. View at Publisher · View at Google Scholar · View at Scopus
  71. Y. M. Shah, K. Morimura, Q. Yang, T. Tanabe, M. Takagi, and F. J. Gonzalez, “Peroxisome proliferator-activated receptor α regulates a microRNA-mediated signaling cascade responsible for hepatocellular proliferation,” Molecular and Cellular Biology, vol. 27, no. 12, pp. 4238–4247, 2007. View at Publisher · View at Google Scholar · View at Scopus
  72. N. Calo, P. Ramadori, C. Sobolewski et al., “Stress-activated miR-21/miR-21 in hepatocytes promotes lipid and glucose metabolic disorders associated with high-fat diet consumption,” Gut, vol. 65, no. 11, pp. 1871–1881, 2016. View at Publisher · View at Google Scholar
  73. J. Ji, J. Zhang, G. Huang, J. Qian, X. Wang, and S. Mei, “Over-expressed microRNA-27a and 27b influence fat accumulation and cell proliferation during rat hepatic stellate cell activation,” FEBS Letters, vol. 583, no. 4, pp. 759–766, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. M. Karbiener and M. Scheideler, “MicroRNA functions in brite/brown fat—novel perspectives towards anti-obesity strategies,” Computational and Structural Biotechnology Journal, vol. 11, no. 19, pp. 101–105, 2014. View at Publisher · View at Google Scholar · View at Scopus
  75. Y. Wu, J. Zuo, Y. Zhang et al., “Identification of miR-106b-93 as a negative regulator of brown adipocyte differentiation,” Biochemical and Biophysical Research Communications, vol. 438, no. 4, pp. 575–580, 2013. View at Publisher · View at Google Scholar · View at Scopus
  76. D. Iliopoulos, K. N. Malizos, P. Oikonomou, and A. Tsezou, “Integrative MicroRNA and proteomic approaches identify novel osteoarthritis genes and their collaborative metabolic and inflammatory networks,” PLoS ONE, vol. 3, no. 11, article e3740, 2008. View at Publisher · View at Google Scholar · View at Scopus
  77. W.-L. W. Wang, J. E. Welsh, and M. Tenniswood, “1,25-Dihydroxyvitamin D3 modulates lipid metabolism in prostate cancer cells through miRNA mediated regulation of PPARA,” The Journal of Steroid Biochemistry and Molecular Biology, vol. 136, no. 1, pp. 247–251, 2013. View at Publisher · View at Google Scholar · View at Scopus
  78. L. Salvadó, L. Serrano-Marco, E. Barroso, X. Palomer, and M. Vázquez-Carrera, “Targeting PPARβ/δ for the treatment of type 2 diabetes mellitus,” Expert Opinion on Therapeutic Targets, vol. 16, no. 2, pp. 209–223, 2012. View at Publisher · View at Google Scholar
  79. S. A. Ross and C. D. Davis, “MicroRNA, nutrition, and cancer prevention,” Advances in Nutrition, vol. 2, no. 6, pp. 472–485, 2011. View at Publisher · View at Google Scholar · View at Scopus
  80. C. H. Lee, P. Olson, A. Hevener et al., “PPARdelta regulates glucose metabolism and insulin sensitivity,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 9, pp. 3444–3449, 2006. View at Google Scholar
  81. Y.-X. Wang, C.-H. Lee, S. Tiep et al., “Peroxisome-proliferator-activated receptor δ activates fat metabolism to prevent obesity,” Cell, vol. 113, no. 2, pp. 159–170, 2003. View at Publisher · View at Google Scholar · View at Scopus
  82. E. Ehrenborg and A. Krook, “Regulation of skeletal muscle physiology and metabolism by peroxisome proliferator-activated receptor δ,” Pharmacological Reviews, vol. 61, no. 3, pp. 373–393, 2009. View at Publisher · View at Google Scholar · View at Scopus
  83. B. Gross, M. Pawlak, P. Lefebvre, and B. Staels, “PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD,” Nature Reviews Endocrinology, vol. 13, no. 1, pp. 36–49, 2016. View at Publisher · View at Google Scholar
  84. R. L. Stephen, M. C. U. Gustafsson, M. Jarvis et al., “Activation of peroxisome proliferator-activated receptor δ stimulates the proliferation of human breast and prostate cancer cell lines,” Cancer Research, vol. 64, no. 9, pp. 3162–3170, 2004. View at Publisher · View at Google Scholar · View at Scopus
  85. J. M. Peters, F. J. Gonzalez, and R. Müller, “Establishing the Role of PPARβ/δ in Carcinogenesis,” Trends in Endocrinology & Metabolism, vol. 26, no. 11, pp. 595–607, 2015. View at Publisher · View at Google Scholar
  86. D. Gatfield, G. Le Martelot, C. E. Vejnar et al., “Integration of microRNA miR-122 in hepatic circadian gene expression,” Genes and Development, vol. 23, no. 11, pp. 1313–1326, 2009. View at Publisher · View at Google Scholar · View at Scopus
  87. M. Aprile, M. R. Ambrosio, V. D'Esposito et al., “PPARG in human adipogenesis: differential contribution of canonical transcripts and dominant negative isoforms,” PPAR Research, vol. 2014, Article ID 537865, 11 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  88. M. Pancione, L. Sabatino, A. Fucci et al., “Epigenetic silencing of peroxisome proliferator-activated receptor γ is a biomarker for colorectal cancer progression and adverse patients' outcome,” PLoS ONE, vol. 5, no. 12, Article ID e14229, 2010. View at Publisher · View at Google Scholar · View at Scopus
  89. M. Peyrou, P. Ramadori, L. Bourgoin, and M. Foti, “PPARs in liver diseases and cancer: epigenetic regulation by microRNAs,” PPAR Research, vol. 2012, Article ID 757803, 16 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  90. J. Mann, D. C. K. Chu, A. Maxwell et al., “MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis,” Gastroenterology, vol. 138, no. 2, pp. 705.e4–714.e4, 2010. View at Publisher · View at Google Scholar · View at Scopus
  91. T. Shirasaki, M. Honda, T. Shimakami et al., “MicroRNA-27a regulates lipid metabolism and inhibits hepatitis C virus replication in human hepatoma cells,” Journal of Virology, vol. 87, no. 9, pp. 5270–5286, 2013. View at Publisher · View at Google Scholar · View at Scopus
  92. L. Q. Cao, X. L. Wang, Q. Wang et al., “Rosiglitazone sensitizes hepatocellular carcinoma cell lines to 5-fluorouracil antitumor activity through activation of the PPARgamma signaling pathway,” Acta Pharmacologica Sinica, vol. 30, no. 9, pp. 1316–1322, 2009. View at Google Scholar
  93. J. Yu, B. Shen, E. S. H. Chu et al., “Inhibitory role of peroxisome proliferator-activated receptor gamma in hepatocarcinogenesis in mice and in vitro,” Hepatology, vol. 51, no. 6, pp. 2008–2019, 2010. View at Publisher · View at Google Scholar · View at Scopus
  94. K. L. Schaefer, K. Wada, H. Takahashi et al., “Peroxisome proliferator-activated receptor γ inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells,” Cancer Research, vol. 65, no. 6, pp. 2251–2259, 2005. View at Publisher · View at Google Scholar · View at Scopus
  95. K. Yoshizawa, D. P. Cioca, S. Kawa, E. Tanaka, and K. Kiyosawa, “Peroxisome proliferator-activated receptor γ ligand troglitazone induces cell cycle arrest and apoptosis of hepatocellular carcinoma cell lines,” Cancer, vol. 95, no. 10, pp. 2243–2251, 2002. View at Publisher · View at Google Scholar · View at Scopus
  96. A. Panza, C. Votino, A. Gentile et al., “Peroxisome proliferator-activated receptor γ-mediated induction of microRNA-145 opposes tumor phenotype in colorectal cancer,” Biochimica et Biophysica Acta—Molecular Cell Research, vol. 1843, no. 6, pp. 1225–1236, 2014. View at Publisher · View at Google Scholar · View at Scopus
  97. B.-C. Jeong, I.-H. Kang, and J.-T. Koh, “MicroRNA-302a inhibits adipogenesis by suppressing peroxisome proliferator-activated receptor γ expression,” FEBS Letters, vol. 588, no. 18, pp. 3427–3434, 2014. View at Publisher · View at Google Scholar · View at Scopus
  98. Q. Lin, Z. Gao, R. M. Alarcon, J. Ye, and Z. Yun, “A role of miR-27 in the regulation of adipogenesis,” FEBS Journal, vol. 276, no. 8, pp. 2348–2358, 2009. View at Publisher · View at Google Scholar · View at Scopus
  99. H. Li, T. Li, S. Wang et al., “MiR-17-5p and miR-106a are involved in the balance between osteogenic and adipogenic differentiation of adipose-derived mesenchymal stem cells,” Stem Cell Research, vol. 10, no. 3, pp. 313–324, 2013. View at Publisher · View at Google Scholar · View at Scopus
  100. M. Sun, X. Zhou, L. Chen et al., “The regulatory roles of microRNAs in bone remodeling and perspectives as biomarkers in osteoporosis,” BioMed Research International, vol. 2016, Article ID 1652417, 11 pages, 2016. View at Publisher · View at Google Scholar
  101. C. S. Lutz and A. L. Cornett, “Regulation of genes in the arachidonic acid metabolic pathway by RNA processing and RNA-mediated mechanisms,” Wiley Interdisciplinary Reviews: RNA, vol. 4, no. 5, pp. 593–605, 2013. View at Publisher · View at Google Scholar · View at Scopus
  102. A. Croasdell, P. F. Duffney, N. Kim, S. H. Lacy, P. J. Sime, and R. P. Phipps, “PPARγ and the innate immune system mediate the resolution of inflammation,” PPAR Research, vol. 2015, Article ID 549691, 20 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  103. B. Kang, K. K. Park, J. M. Kleinhenz et al., “Peroxisome proliferator–activated receptor γ and microRNA 98 in hypoxia-induced endothelin-1 signaling,” American Journal of Respiratory Cell and Molecular Biology, vol. 54, no. 1, pp. 136–146, 2016. View at Publisher · View at Google Scholar
  104. D. E. Green, R. L. Sutliff, and C. M. Hart, “Is peroxisome proliferator-activated receptor gamma (PPARγ) a therapeutic target for the treatment of pulmonary hypertension?” Pulmonary Circulation, vol. 1, no. 1, pp. 33–47, 2011. View at Publisher · View at Google Scholar
  105. T. Liu, H. Tang, Y. Lang, M. Liu, and X. Li, “MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin,” Cancer Letters, vol. 273, no. 2, pp. 233–242, 2009. View at Publisher · View at Google Scholar · View at Scopus
  106. Y. Tsuchiya, M. Nakajima, S. Takagi, T. Taniya, and T. Yokoi, “MicroRNA regulates the expression of human cytochrome P450 1B1,” Cancer Research, vol. 66, no. 18, pp. 9090–9098, 2006. View at Publisher · View at Google Scholar · View at Scopus
  107. R. Zhou, X. Li, G. Hu, A.-Y. Gong, K. M. Drescher, and X.-M. Chen, “MiR-16 targets transcriptional corepressor SMRT and modulates NF-kappaB-regulated transactivation of interleukin-8 gene,” PLoS ONE, vol. 7, no. 1, Article ID e30772, 2012. View at Publisher · View at Google Scholar · View at Scopus
  108. L. Tombolan, M. Zampini, S. Casara et al., “MicroRNA-27a contributes to rhabdomyosarcoma cell proliferation by suppressing RARA and RXRA,” PLoS ONE, vol. 10, no. 4, Article ID e0125171, 2015. View at Publisher · View at Google Scholar · View at Scopus
  109. Y. Oda, M. Nakajima, K. Tsuneyama et al., “Retinoid X receptor α in human liver is regulated by miR-34a,” Biochemical Pharmacology, vol. 90, no. 2, pp. 179–187, 2014. View at Publisher · View at Google Scholar · View at Scopus
  110. M. J. Ochs, D. Steinhilber, and B. Suess, “MicroRNA involved in inflammation: control of eicosanoid pathway,” Frontiers in Pharmacology, vol. 2, article no. 39, 2011. View at Publisher · View at Google Scholar · View at Scopus
  111. S.-E. Choi and J. K. Kemper, “Regulation of SIRT1 by microRNAs,” Molecules and Cells, vol. 36, no. 5, pp. 385–392, 2013. View at Publisher · View at Google Scholar · View at Scopus
  112. B. M. Alrfaei, R. Vemuganti, and J. S. Kuo, “microRNA-100 targets SMRT/NCOR2, reduces proliferation, and improves survival in glioblastoma animal models,” PLoS ONE, vol. 8, no. 11, Article ID e80865, 2013. View at Publisher · View at Google Scholar · View at Scopus
  113. D. Guérit, D. Philipot, P. Chuchana et al., “Sox9-regulated miRNA-574-3p inhibits chondrogenic differentiation of mesenchymal stem cells,” PLoS ONE, vol. 8, no. 4, Article ID e62582, 2013. View at Publisher · View at Google Scholar · View at Scopus
  114. Y. K. Adlakha, S. Khanna, R. Singh, V. P. Singh, A. Agrawal, and N. Saini, “Pro-apoptotic miRNA-128-2 modulates ABCA1, ABCG1 and RXRα expression and cholesterol homeostasis,” Cell Death & Disease, vol. 4, article e780, 2013. View at Google Scholar · View at Scopus
  115. P. Seale, B. Bjork, W. Yang et al., “PRDM16 controls a brown fat/skeletal muscle switch,” Nature, vol. 454, no. 7207, pp. 961–967, 2008. View at Publisher · View at Google Scholar · View at Scopus
  116. H. Yin, A. Pasut, V. D. Soleimani et al., “MicroRNA-133 controls brown adipose determination in skeletal muscle satellite cells by targeting Prdm16,” Cell Metabolism, vol. 17, no. 2, pp. 210–224, 2013. View at Publisher · View at Google Scholar · View at Scopus
  117. M. Trajkovski, K. Ahmed, C. C. Esau, and M. Stoffel, “MyomiR-133 regulates brown fat differentiation through Prdm16,” Nature Cell Biology, vol. 14, no. 12, pp. 1330–1335, 2012. View at Publisher · View at Google Scholar · View at Scopus
  118. R. B. Vega, J. M. Huss, and D. P. Kelly, “The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor α in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes,” Molecular and Cellular Biology, vol. 20, no. 5, pp. 1868–1876, 2000. View at Publisher · View at Google Scholar · View at Scopus
  119. Z. Fang, P. Li, W. Jia, T. Jiang, Z. Wang, and Y. Xiang, “miR-696 plays a role in hepatic gluconeogenesis in ob/ob mice by targeting PGC-1α,” International Journal of Molecular Medicine, vol. 38, no. 3, pp. 845–852, 2016. View at Publisher · View at Google Scholar
  120. J.-Y. Huang, S.-F. Chou, J.-W. Lee et al., “MicroRNA-130a can inhibit hepatitis B virus replication via targeting PGC1α and PPARγ,” RNA, vol. 21, no. 3, pp. 385–400, 2015. View at Publisher · View at Google Scholar · View at Scopus
  121. C. Cantó and J. Auwerx, “Targeting sirtuin 1 to improve metabolism: all you need is NAD+?” Pharmacological Reviews, vol. 64, no. 1, pp. 166–187, 2012. View at Publisher · View at Google Scholar · View at Scopus
  122. H. Yin, M. Hu, R. Zhang, Z. Shen, L. Flatow, and M. You, “MicroRNA-217 promotes ethanol-induced fat accumulation in hepatocytes by down-regulating SIRT1,” Journal of Biological Chemistry, vol. 287, no. 13, pp. 9817–9826, 2012. View at Publisher · View at Google Scholar · View at Scopus
  123. B. Zhou, C. Li, W. Qi et al., “Downregulation of miR-181a upregulates sirtuin-1 (SIRT1) and improves hepatic insulin sensitivity,” Diabetologia, vol. 55, no. 7, pp. 2032–2043, 2012. View at Publisher · View at Google Scholar · View at Scopus
  124. C. L. Kurtz, E. E. Fannin, C. L. Toth, D. S. Pearson, K. C. Vickers, and P. Sethupathy, “Inhibition of miR-29 has a significant lipid-lowering benefit through suppression of lipogenic programs in liver,” Scientific Reports, vol. 5, Article ID 12911, 2015. View at Publisher · View at Google Scholar · View at Scopus
  125. X.-F. Tian, F.-J. Ji, H.-L. Zang, and H. Cao, “Activation of the miR-34a/SIRT1/p53 signaling pathway contributes to the progress of liver fibrosis via inducing apoptosis in hepatocytes but not in HSCs,” PLoS ONE, vol. 11, no. 7, Article ID e0158657, 2016. View at Publisher · View at Google Scholar
  126. F. Zhang, J. Cui, X. Liu et al., “Roles of microRNA-34a targeting SIRT1 in mesenchymal stem cells,” Stem Cell Research and Therapy, vol. 6, no. 1, article 195, 2015. View at Publisher · View at Google Scholar · View at Scopus
  127. A. L. McCubbrey, J. D. Nelson, V. R. Stolberg et al., “MicroRNA-34a negatively regulates efferocytosis by tissue macrophages in part via SIRT1,” Journal of Immunology, vol. 196, no. 3, pp. 1366–1375, 2016. View at Publisher · View at Google Scholar · View at Scopus
  128. K. Duan, Y.-C. Ge, X.-P. Zhang et al., “miR-34a inhibits cell proliferation in prostate cancer by downregulation of SIRT1 expression,” Oncology Letters, vol. 10, no. 5, pp. 3223–3227, 2015. View at Publisher · View at Google Scholar · View at Scopus
  129. X. Liu, X. Chen, X. Yu et al., “Regulation of microRNAs by epigenetics and their interplay involved in cancer,” Journal of Experimental and Clinical Cancer Research, vol. 32, no. 1, article 96, 2013. View at Publisher · View at Google Scholar · View at Scopus
  130. S. Luo, J. Wang, Y. Ma, Z. Yao, and H. Pan, “PPARγ inhibits ovarian cancer cells proliferation through upregulation of miR-125b,” Biochemical and Biophysical Research Communications, vol. 462, no. 2, pp. 85–90, 2015. View at Publisher · View at Google Scholar · View at Scopus
  131. H.-Y. Zhu, C. Li, Z. Zheng et al., “Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist inhibits collagen synthesis in human hypertrophic scar fibroblasts by targeting Smad3 via miR-145,” Biochemical and Biophysical Research Communications, vol. 459, no. 1, pp. 49–53, 2015. View at Publisher · View at Google Scholar · View at Scopus
  132. Y. Zhang, Z. Yang, R. Whitby, and L. Wang, “Regulation of miR-200c by nuclear receptors PPARα, LRH-1 and SHP,” Biochemical and Biophysical Research Communications, vol. 416, no. 1-2, pp. 135–139, 2011. View at Publisher · View at Google Scholar · View at Scopus
  133. W. Ying, A. Tseng, R. C.-A. Chang et al., “MicroRNA-223 is a crucial mediator of PPARγ-regulated alternative macrophage activation,” Journal of Clinical Investigation, vol. 125, no. 11, pp. 4149–4159, 2015. View at Publisher · View at Google Scholar · View at Scopus
  134. J. Yu, X. Kong, J. Liu et al., “Expression profiling of PPARγ-regulated MicroRNAs in human subcutaneous and visceral adipogenesis in both genders,” Endocrinology, vol. 155, no. 6, pp. 2155–2165, 2014. View at Publisher · View at Google Scholar · View at Scopus
  135. C.-M. Wong, L. Wei, S. L.-K. Au et al., “MiR-200b/200c/429 subfamily negatively regulates Rho/ ROCK signaling pathway to suppress hepatocellular carcinoma metastasis,” Oncotarget, vol. 6, no. 15, pp. 13658–13670, 2015. View at Publisher · View at Google Scholar · View at Scopus
  136. X. Fang, L. Fang, A. Liu, X. Wang, B. Zhao, and N. Wang, “Activation of PPAR-δ induces microRNA-100 and decreases the uptake of very low-density lipoprotein in endothelial cells,” British Journal of Pharmacology, vol. 172, no. 15, pp. 3728–3736, 2015. View at Publisher · View at Google Scholar · View at Scopus
  137. S.-Y. Liu, Y.-Y. Zhang, Y. Gao et al., “MiR-378 plays an important role in the differentiation of bovine preadipocytes,” Cellular Physiology and Biochemistry, vol. 36, no. 4, pp. 1552–1562, 2015. View at Publisher · View at Google Scholar
  138. E. John, A. Wienecke-Baldacchino, M. Liivrand, M. Heinäniemi, C. Carlberg, and L. Sinkkonen, “Dataset integration identifies transcriptional regulation of microRNA genes by PPARγ in differentiating mouse 3T3-L1 adipocytes,” Nucleic Acids Research, vol. 40, no. 10, pp. 4446–4460, 2012. View at Publisher · View at Google Scholar · View at Scopus
  139. K. Song, C. Han, J. Zhang et al., “Epigenetic regulation of microRNA-122 by peroxisome proliferator activated receptor-gamma and hepatitis b virus X protein in hepatocellular carcinoma cells,” Hepatology, vol. 58, no. 5, pp. 1681–1692, 2013. View at Publisher · View at Google Scholar · View at Scopus
  140. L. G. Tillman, R. S. Geary, and G. E. Hardee, “Oral delivery of antisense oligonucleotides in man,” Journal of Pharmaceutical Sciences, vol. 97, no. 1, pp. 225–236, 2008. View at Publisher · View at Google Scholar · View at Scopus
  141. S. Mitragotri, P. A. Burke, and R. Langer, “Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies,” Nature Reviews Drug Discovery, vol. 13, no. 9, pp. 655–672, 2014. View at Publisher · View at Google Scholar · View at Scopus
  142. X. Wang, B. Yu, W. Ren et al., “Enhanced hepatic delivery of siRNA and microRNA using oleic acid based lipid nanoparticle formulations,” Journal of Controlled Release, vol. 172, no. 3, pp. 690–698, 2013. View at Publisher · View at Google Scholar · View at Scopus
  143. C. J. Cheng, W. M. Saltzman, and J. F. Slack, “Canonical and non-canonical barriers facing antimiR cancer therapeutics,” Current Medicinal Chemistry, vol. 20, no. 29, pp. 3582–3593, 2013. View at Publisher · View at Google Scholar · View at Scopus
  144. S. Pan, X. Yang, Y. Jia, R. Li, and R. Zhao, “Microvesicle-shuttled miR-130b reduces fat deposition in recipient primary cultured porcine adipocytes by inhibiting PPAR-γ expression,” Journal of Cellular Physiology, vol. 229, no. 5, pp. 631–639, 2014. View at Publisher · View at Google Scholar · View at Scopus
  145. S. Pan, X. Yang, Y. Jia et al., “Intravenous injection of microvesicle-delivery miR-130b alleviates high-fat diet-induced obesity in C57BL/6 mice through translational repression of PPAR-γ,” Journal of Biomedical Science, vol. 22, article 86, 2015. View at Publisher · View at Google Scholar · View at Scopus
  146. F. Olivieri, M. R. Rippo, F. Prattichizzo et al., “Toll like receptor signaling in “inflammaging”: microRNA as new players,” Immunity and Ageing, vol. 10, article no. 11, 2013. View at Publisher · View at Google Scholar · View at Scopus
  147. R. E. Lanford, E. S. Hildebrandt-Eriksen, A. Petri et al., “Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection,” Science, vol. 327, no. 5962, pp. 198–201, 2010. View at Publisher · View at Google Scholar · View at Scopus
  148. S. Ottosen, T. B. Parsley, L. Yang et al., “In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122,” Antimicrobial Agents and Chemotherapy, vol. 59, no. 1, pp. 599–608, 2015. View at Publisher · View at Google Scholar · View at Scopus
  149. J. Stenvang, A. Petri, M. Lindow, S. Obad, and S. Kauppinen, “Inhibition of microRNA function by antimiR oligonucleotides,” Silence, vol. 3, no. 1, article 1, 2012. View at Publisher · View at Google Scholar · View at Scopus
  150. K. J. Rayner, C. C. Esau, F. N. Hussain et al., “Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides,” Nature, vol. 478, no. 7369, pp. 404–407, 2011. View at Publisher · View at Google Scholar · View at Scopus
  151. H. Wu, R. Ng, X. Chen, C. J. Steer, and G. Song, “MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1-p53-Srebp1c pathway,” Gut, vol. 65, no. 11, pp. 1850–1860, 2015. View at Publisher · View at Google Scholar · View at Scopus
  152. M. Agostini and R. A. Knight, “miR-34: from bench to bedside,” Oncotarget, vol. 5, no. 4, pp. 872–881, 2014. View at Publisher · View at Google Scholar · View at Scopus
  153. L. E. Young, A. E. Moore, L. Sokol, N. Meisner-Kober, and D. A. Dixon, “The mRNA stability factor HuR inhibits MicroRNA-16 targeting of COX-2,” Molecular Cancer Research, vol. 10, no. 1, pp. 167–180, 2012. View at Publisher · View at Google Scholar · View at Scopus
  154. S. Geisler and J. Coller, “RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts,” Nature Reviews Molecular Cell Biology, vol. 14, no. 11, pp. 699–712, 2013. View at Publisher · View at Google Scholar · View at Scopus